LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma
Pharmaceuticals · 08.10.2025 · 18 (10) · 1509
DOI: 10.3390/ph18101509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.10.2025. Verfasst von Naser F Al-Tannak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait City P.O. Box 46300, Kuwait. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Sector- Kuwait University, Research Sector-Kuwait University.
Abstract (Originalsprache)
Background
A novel triple therapy regimen for Helicobacter pylori eradication, recently approved by the U.S. FDA, comprises vonoprazan (VPN), a potassium-competitive acid blocker, in combination with amoxicillin (AMX) and clarithromycin (CMN). This study presents the development and full validation of a rapid, selective, and sensitive LC-MS/MS method for the simultaneous quantification of these three drugs in spiked human plasma.
Methods
Sample preparation was performed using a simple and efficient liquid–liquid extraction (LLE) technique. Chromatographic separation was achieved within 5 min using a Phenomenex Kinetex C18 column (100 × 4.6 mm, 2.6 µm) and a gradient elution system consisting of 0.1% formic acid in water and acetonitrile. Moreover, diazepam was used as an internal standard. The mass spectrometric detection was conducted in multiple reaction monitoring (MRM) mode using positive electrospray ionization.
Results
The method exhibited excellent linearity over the investigated concentration ranges (2, 5, 10, 20, 50, and 100 ng/mL for amoxicillin and clarithromycin and 5, 10, 20, 30, 50, and 100 ng/mL for vonoprazan). Intra- and inter-day precision and accuracy values met FDA bioanalytical method validation guidelines, with relative standard deviations and relative errors below 15%. Mean absolute recoveries were above 93% for all analytes.
Conclusions
The developed method was fully validated, rapid, selective, and sensitive LC-MS/MS and was assessed using the AGREE tool as a greenness assessment approach, confirming its environmental friendliness and alignment with green analytical chemistry principles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait City P.O. Box 46300, Kuwait.
- Pharmacy College, Al-Esraa University, Baghdad 10069, Iraq.
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161, Cathedral Street, Glasgow G4 0RE 1, UK.
ORCID-Profile: Naser F Al-Tannak, Hani M Hafez, Ahmed Hemdan, Abdullah Aldasem, Ibrahim Khadra
Förderung
- Research Sector- Kuwait University
- Research Sector-Kuwait University
Zitieren
APA
Al-Tannak, N. F., Hafez, H. M., Hemdan, A., Aldasem, A., & Khadra, I. (2025). LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma. Pharmaceuticals, 18(10), 1509. https://doi.org/10.3390/ph18101509
Vancouver
Al-Tannak NF, Hafez HM, Hemdan A, Aldasem A, Khadra I. LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma. Pharmaceuticals. 2025;18(10):1509. doi:10.3390/ph18101509
BibTeX
@article{AlTannak2025,
author = {Al-Tannak, Naser F and Hafez, Hani M and Hemdan, Ahmed and Aldasem, Abdullah and Khadra, Ibrahim},
title = {LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {10},
pages = {1509},
doi = {10.3390/ph18101509}
}
EUVIMED